Diabetes Therapeutics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Diabetes Type (Type 1, Type 2, And Gestational), By Drug Type (Oral Antidiabetics (Sulfonylurea, Metformin, Dipeptidyl Peptidase-4 Inhibitors (DPP-4i), Sodium-Glucose Transport Protein-2 Inhibitors (SGLT-2i), &Glucagon-Like Peptide-1Agonist (GLP-1A), And Injectable Anti-Diabetics (Humulin RU 100, Novolin R Flex Pen, Fiasp, Novolog Flex Pen &Insulin Lispro), By End Users (Hospitals, Personal Use, And Clinics), and Region Forecast 2019-2030

The diabetes therapeutics market size was valued at US$ 310.7 billion in 2023 and is projected to grow at a CAGR of 4.2% from 2024-2030.  The diabetes therapeutic market is driven by numerous factors, including genetics, a high-glucose diet, environmental conditions, and obesity, which contribute to the development of diabetes. Additionally, as older people are more likely to develop diabetes, the growing geriatric population supports the market's expansion.

However, it is anticipated that the adverse effects of anti-diabetes market expansion. The rising incidence of type-2 diabetes is likely to make the oral-antidiabetic medication (OAD) market attractive for both new and established competitors. Diabetes type-1, which is insulin-dependent, is treated with injectables like human insulin analogs. Because of the rising incidence of diabetes, the existence of important actors, and the rise in consumer disposable income, North America is the region with the highest application of diabetes therapy. Diabetes type 2 is caused by socioeconomic, demographic, environmental, and hereditary variables, and affects more than 90% of diabetics. With, result increase in the prevalence of diabetes population contributes to the diabetes therapeutics market growth.

Moreover, genetics and family history are connected to diabetes and can be inherited. Diabetes is not always inherited, although those who have a family history of the disease are more likely to have it. Additionally, rising public knowledge of diabetes self-management helps to market expansion. The market is expanding due to government initiatives to provide diabetes care facilities and the development of economical and effective diabetic therapies like oral hypoglycaemic medications.

Key Developments

• In April 2023: Aspects biosystem and Novo Nordisk, agreed to create bio-printed tissue therapeutics that are intended to replace, repair, or supplement biological function within the body to produce a new class of truly disease-modifying treatments for diabetes and obesity.
• In March 2023: Sanofi agreed to purchase Prevention Bio, under an agreement reached with Prevention Bio, Inc. A publicly traded Biopharmaceutical company with a US base that specializes in detecting and treating immune illnesses like Type 1 Diabetes.